Pfizer Extends Subsequent Offering Period of Tender Offer for Shares of Encysive Pharmaceuticals

  
    
  
  
    
      Pfizer Inc (NYSE: PFE) announced today that Explorer Acquisition Corp., 
      a wholly-owned subsidiary of Pfizer, has extended the subsequent 
      offering period of its tender offer for all of the outstanding shares of 
      common stock of Encysive Pharmaceuticals Inc. (NASDAQ: ENCY) to 5:00 
      p.m., New York City time, on April 14, 2008. Pursuant to the tender 
      offer, Explorer Acquisition Corp. is offering to purchase shares of 
      Encysive at a purchase price of $2.35 per share, net to the seller in 
      cash, without interest thereon and less any required withholding taxes. 
      The subsequent offering period had been previously scheduled to expire 
      at 5:00 p.m., New York City time, on April 7, 2008. According to the 
      depositary for the offer, a total of 67,435,726 shares (representing 
      approximately 83.3% of the outstanding shares), had been tendered prior 
      to such time.
    
    
      Georgeson is the Information Agent for the tender offer. For questions 
      and information about the tender offer and subsequent offering period, 
      please call Georgeson at [phone] (banks and brokerage firms) or 
      toll-free at [phone] (stockholders and all others).
    
    
      Additional Information
    
    
      This press release is for informational purposes only and is neither an 
      offer to purchase nor a solicitation of an offer to sell securities. The 
      tender offer has been made pursuant to a tender offer statement and 
      related materials. The tender offer statement (including the offer to 
      purchase, letter of transmittal and related tender offer documents) 
      filed by Pfizer with the Securities and Exchange Commission (the “SEC”) 
      and the solicitation/recommendation statement filed by Encysive with the 
      SEC contain important information which should be read carefully before 
      any decision is made with respect to the tender offer. The offer to 
      purchase and related materials as well as the 
      solicitation/recommendation statement may be obtained by Encysive 
      stockholders at no charge by directing a request by mail to Georgeson 
      Inc., 199 Water Street, 26th Floor, New York, NY 10038, or by calling 
      toll-free at [phone], and may also be obtained at no charge at 
      the website maintained by the SEC at http://www.sec.gov.
    
    
      DISCLOSURE NOTICE: The information contained in this press release is 
      as of April 8, 2008. Except as required by law, Pfizer assumes no 
      obligation to update any forward-looking statements contained in this 
      release as a result of new information or future events or developments. 
      Some statements in this release may constitute forward-looking 
      statements. Pfizer cautions that these forward-looking statements are 
      subject to risks and uncertainties that may cause actual results to 
      differ materially from those indicated in the forward-looking 
      statements, including the risk that the merger following the tender 
      offer may not be consummated for various reasons, including the failure 
      to satisfy the conditions precedent to the completion of the 
      acquisition. A further list and description of risks and uncertainties 
      can be found in Pfizer’s Annual Report on Form 
      10-K for the fiscal year ended December 31, 2007 and in its subsequently 
      filed reports on Form 8-K.